Henry Johnson

Head of Chemistry

Dr. Johnson brings more than 16 years of drug discovery and development experience to BridGene.  He arrived after a six-year span as a Director at Kezar Life Sciences where he was a primary contributor to the discovery and development of the company’s clinical assets, including KZR-616, a first-in-class selective immunoproteasome inhibitor for the treatment of autoimmune disease. Prior to Kezar, he held positions of increasing responsibility within the industry, contributing his expertise to several programs that advanced into the clinic including the approved therapy MINNEBRO®. He is an author on over 40 scientific publications and patents spanning diverse therapeutic areas.

Dr. Johnson earned a Ph.D. in Chemistry from the University of Utah and a B.S. in Biochemistry from California Polytechnic University.